Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSE: Omalizumab vs ICS Boost for Fall Asthma Exacerbations
NCT01430403Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in asthma, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01430403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01430403.